Suven Pharmaceuticals Ltd

₹ 488 -0.77%
02 Feb 2:06 p.m.
About

Suven Pharma is in the business of Contract development & manufacturing organisation (CDMO), catering to the needs of global Pharma Industry.

Key Points

Business Segments
CDMO (Development projects and Commercial supplies)
SPL engages in NCE molecule development and supply of intermediates. This is a high-value-add, high-margin business. SPL supplies intermediates for four molecules addressing rheumatoid arthritis, diabetes, depression and women’s health[1]. This segment makes up 78% of revenues. The company has a strong order book with new clients being consistently added. Most clients are the Big Pharma companies in Europe and the US. The company is looking to shift from Intermediate to API manufacturing and is in discussion with clients regarding this. The company has stated that it has the facilities for API manufacturing.[2]

  • Market Cap 12,430 Cr.
  • Current Price 488
  • High / Low 632 / 388
  • Stock P/E 28.8
  • Book Value 59.0
  • Dividend Yield 0.41 %
  • ROCE 40.8 %
  • ROE 29.8 %
  • Face Value 1.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 34.9%
  • Company has been maintaining a healthy dividend payout of 20.7%

Cons

  • Stock is trading at 8.31 times its book value
  • Debtor days have increased from 51.2 to 65.4 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
273 179 185 238 237 275 259 264 301 392 364 339 278
147 99 108 126 140 138 165 149 179 206 207 188 179
Operating Profit 125 80 77 112 98 137 94 115 122 186 157 151 100
OPM % 46% 45% 41% 47% 41% 50% 36% 43% 40% 48% 43% 45% 36%
9 11 26 16 9 21 22 29 22 65 17 11 11
Interest 4 8 7 3 3 2 2 2 1 1 2 1 0
Depreciation 6 6 7 7 8 9 8 9 9 11 10 12 12
Profit before tax 124 78 89 118 97 148 105 133 134 239 161 149 98
Tax % 25% 25% 17% 22% 24% 23% 21% 21% 28% 33% 43% 28% 27%
Net Profit 93 58 74 92 74 114 83 105 97 160 92 108 72
EPS in Rs 4,650.00 2,895.50 2.91 3.59 2.91 4.46 3.27 4.13 3.81 6.29 3.60 4.22 2.83
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
378 834 1,010 1,320 1,373
206 449 567 738 779
Operating Profit 172 385 443 582 594
OPM % 45% 46% 44% 44% 43%
1 66 68 133 104
Interest 3 23 12 9 5
Depreciation 12 24 32 39 44
Profit before tax 158 405 468 668 648
Tax % 31% 22% 23% 32%
Net Profit 109 317 362 454 431
EPS in Rs 5,463.50 12.45 14.23 17.83 16.94
Dividend Payout % 0% 20% 14% 28%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 52%
TTM: 25%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 55%
TTM: 8%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -11%
Return on Equity
10 Years: %
5 Years: %
3 Years: 35%
Last Year: 30%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
13 13 25 25 25
Reserves 578 832 1,155 1,502 1,478
83 186 143 97 91
123 142 151 205 211
Total Liabilities 783 1,173 1,474 1,830 1,806
271 357 441 534 670
CWIP 111 102 96 30 87
Investments 7 338 542 598 444
394 376 395 667 604
Total Assets 783 1,173 1,474 1,830 1,806

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022
50 407 383 330
-65 -413 -311 -136
26 7 -76 -156
Net Cash Flow 11 1 -5 37

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 142 51 37 65
Inventory Days 556 278 243 259
Days Payable 190 113 100 97
Cash Conversion Cycle 509 217 180 228
Working Capital Days 285 105 95 126
ROCE % 49% 40% 41%

Shareholding Pattern

Numbers in percentages

Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
60.00 60.00 60.00 60.00 60.00 60.00 60.00 60.00 60.00 60.00 60.00 60.00
4.24 3.55 4.15 6.04 6.93 7.93 8.03 8.25 8.56 8.49 7.58 8.11
3.95 4.61 4.99 4.66 5.52 5.45 5.81 5.93 6.56 6.96 10.87 11.36
31.81 31.84 30.86 29.30 27.55 26.62 26.16 25.82 24.88 24.55 21.56 20.55

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls